Office of Technology Transfer – University of Michigan

Novel therapeutic method involving Down syndrome cell adhesion molecule (Dscam) to treat neurological and mental disorders

Technology #5991

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Bing Ye
Managed By
Tiefei Dong
Senior Licensing Specialist, Life Sciences 734-763-5332
Patent Protection
US Patent Pending
Publications
Dscam Expression Levels Determine Presynaptic Arbor Sizes in Drosophila Sensory Neurons
Neuron, Volume 78, Issue 5, 827-838, 5 June 2013, 2013

Dysregulation of Down syndrome cell adhesion molecule (Dscam) expression has been implicated in many neurological and mental disorders including Down syndrome, Fragile X syndrome, bipolar disorder and intractable epilepsy. Particularly, increased Dscam protein levels have been found to induce overgrowth of axon terminals in developing neurons, which is a major contributor to the pathogenesis of these disorders. There are currently no effective treatments for these neurological disorders, and scientists are only beginning to understand the Dscam regulated pathway.

Novel mediator of Dscam induced aberrant axonal growth

Investigators at the University of Michigan have identified a protein that is a critical mediator of the Dscam induced aberrant axonal growth. In Drosophila melanogaster, mutations in this protein mediator completely suppressed axonal overgrowth due to Dscam overexpression without affecting Dscam expression levels itself, suggesting the protein is essential for Dscam induced axonal overgrowth. Moreover, the investigators indentified an inhibitor of this protein that was able to effectively reduce its activity and Dscam induced axonal overgrowth in Drosophila larvae. This exciting finding could provide a potential therapeutic to treat these currently untreatable neurological and mental disorders.

Applications

  • Novel target for neurological and mental disorders
  • Novel therapeutic for neurological and mental disorders

Advantages

  • Protein inhibitor therapeutic is already FDA approved for treatment of other disorders
  • Protein inhibitor therapeutic has been shown to cross the blood-brain barriers, making it effective for treatment of neurological disorders.